Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Incyte Corporation (INCY) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 22,082,490
  • Shares Outstanding, K 188,000
  • Annual Sales, $ 753,750 K
  • Annual Income, $ 6,530 K
  • 36-Month Beta 0.83
  • Price/Sales 21.58
  • Price/Book 59.56

Price Performance

See More
Period Period Low Period High Performance
1-Month
99.25 +18.31%
on 12/30/16
122.68 -4.29%
on 01/20/17
+14.48 (+14.07%)
since 12/23/16
3-Month
83.01 +41.45%
on 11/04/16
122.68 -4.29%
on 01/20/17
+29.70 (+33.86%)
since 10/21/16
52-Week
55.00 +113.49%
on 02/11/16
122.68 -4.29%
on 01/20/17
+38.02 (+47.88%)
since 01/22/16

Most Recent Stories

More News
Lilly-Incyte Rheumatoid Arthritis Drug PDUFA Date Extended

Eli Lilly and Company (LLY) and Incyte Corporation (INCY) announced that the FDA has extended the time to review the company's NDA for baricitinib for the treatment of rheumatoid arthritis (RA).

U.S. FDA Extends Review Period for Baricitinib, an Investigational Rheumatoid Arthritis Treatment

Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that the U.S. Food and Drug Administration (FDA) has extended the review period for the new drug application (NDA)...

4 Stocks in Focus as Biotech M&A Hopes Surge on Takeda-ARIAD Deal

Takeda to Buy ARIAD, More M&As to Follow in Biotech Sector?

Incyte/Merck to Start More Epacadostat-Keytruda Studies

Incyte (INCY) and Merck (MRK) announced that they have decided to initiate additional pivotal studies on epacadostat, in combination with Merck's Keytruda.

Bluerock Residential Growth REIT, Cal-Maine Foods, Incyte, Eli Lilly and Synergy Pharmaceuticals highlighted as Zacks Bull and Bear of the Day

Bluerock Residential Growth REIT, Cal-Maine Foods, Incyte, Eli Lilly and Synergy Pharmaceuticals highlighted as Zacks Bull and Bear of the Day

Incyte Treats First Patient in Phase II GVHD Study on Jakafi

Incyte Corporation (INCY) announced that the first patient has been treated in the pivotal phase II REACH-1 study assessing its marketed drug Jakafi, in combination with corticosteroids, for the treatment...

Two Key FDA Decisions to Watch Out for in January 2017

Incyte (INCY) and Synergy (SGYP) have important regulatory events coming up this month.

Incyte Announces First Patient Treated in Pivotal Clinical Trial Program for Ruxolitinib (Jakafi(R)) in Graft-versus-Host Disease

Incyte Corporation (Nasdaq:INCY) today announced that the first patient has been treated in the REACH-1 pivotal Phase 2 trial evaluating ruxolitinib (Jakafi(R)) in combination with corticosteroids...

The Zacks Analyst Blog Highlights: Alexion Pharmaceuticals, Celgene, Incyte, Eli Lilly, Regeneron Pharmaceuticals and Ophthotech

The Zacks Analyst Blog Highlights: Alexion Pharmaceuticals, Celgene, Incyte, Eli Lilly, Regeneron Pharmaceuticals and Ophthotech

Forget Alexion (ALXN), Buy These 3 Biotech Stocks Instead

We advise investors to focus on biotech stocks which sport a strong Zacks Rank and have interesting pipelines/products and growth potential.

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Incyte Corp is a drug discovery company that is using its expertise in genomics, medicinal chemistry and molecular, cellular and in vivo biology to discover and develop novel therapeutics. The company has three fully-staffed drug discovery programs underway focused primarily on the identification of...

See More

Support & Resistance

2nd Resistance Point 120.37
1st Resistance Point 118.89
Last Price 117.42
1st Support Level 116.31
2nd Support Level 115.21

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.